{
    "nctId": "NCT00979641",
    "briefTitle": "Biweekly Avastin and Docetaxel as the First Line Treatment for Patients With Metastatic Breast Cancer",
    "officialTitle": "Single Arm Study of the Combination of Biweekly Avastin and Docetaxel as the First Line Treatment for Patients With Metastatic Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 65,
    "primaryOutcomeMeasure": "progression free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* written informed concent\n* age \\> or equal 18 years\n* able to comply with the protocol\n* histologically or cytologically confirmed, Her-2 negative, adenocarcinoma of the breast with measurable or nonmeasurable metastatic disease, chemotherapy indicated\n* ECOG 0-2, life expectancy of over or qual to 12 wks\n* prior neo/adjuvant chemotherapy allowed\n* prior adjuvant taxane therapy is allowed, DFS\\> or equal 6 months\n* previous hormonal therapy allowed\n* prior RT is allowed as adjuvant setting or to relief of metastatic bone pain, no more than 30% of marrow-bearing bone irradiated\n* Adequate haematological function\n* adequate liver function total bilirubin \\<1.5 x upper limit of normal and AST,ALT \\<2.5 x ULN in patients without liver metastases; \\<5 x ULN in patients with liver metastases\n* adequate renal function serum creatinine \\<or equal 1,5x ULN or calculated creatinine clearance \\> or equal 50mL/min and urine dipstick for proteinuria \\<2+. Patients discovered to have or equal proteinuria or dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate \\< or equal 1 g of protein in 24 hours\n* INR\\<or equal 1.5 and PTT\\< or equal 1.5 x ULN within 7 days prior to enrolment. Anticoagulation treatment not allowed\n* if female, should not be pregnant or breast-feeding. Women with an intact uterus must have a negative serum pregnancy test within 28 days prior to inclusion into the study\n\nExclusion Criteria:\n\n* previous chemotherapy for mBC\n* radiation therapy for the treatment of metastatic disease within 28 days\n* evidence of CNS metastases. If symptomatic, the patient should be scanned within 28 days to enrolment to rule out CNS metastases\n* pre-existing peripheral neuropathy NCI CTC-AE grade \\> 2 at enrolment\n* major surgery, significant traumatic injury within 28 days prior to enrolment or anticipation of the need for major surgery during study treatment\n* Minor surgery, including insertion off an indwelling catheter, within 24 hours prior to the first line bevacizumab infusion\n* Current or recent(within 10 da\u00ffs of first dose of bevacizumab) use of aspirin (\\>325mg/day)\n* current or recent (within 10 days of first dose of bevacizumab) use of oral or parenteral anticoagulants or thrombolytic agents.\n* history of evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding\n* uncontrolled hypertension (systolic \\>150mmHg and/or diastolic\\>100mmHg)\n* Clinically significant cardiovascular disease for example CVA, myocardial infarction, unstable angina, congestive heart failure NYHA Class \\> or equal II, serious cardiac arrhythmia requiring medication during the study, which might interfere with regularity of the study treatment, or not controlled by medication\n* non- healing wound, active peptic ulcer or bone fracture\n* history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of enrolment\n* past of current history (within the last 5 years) of other malignancies except curatively treated basal and squamous cell carcinoma of the skin or in-situ carcinoma of the cervix\n* treatment with any other investigational agent, or participation in another clinical drug trial within 28 days prior to enrolment\n* evidence of any other disease, neurological, psychiatric or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications\n* history of thrombotic disorders within last six months",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}